Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
π Gilead shares returned -4.4% over the past month, underperforming the S&P 500's +5.4% gain.
π The company is expected to post a quarterly loss of $5.31 per share, down 364.2% year-over-year.
π Consensus earnings estimates for the current fiscal year are -$0.79, reflecting a 109.7% decline from the prior year.
π° Revenue estimates indicate growth, with the current quarter projected at $7.39 billion (+4.3% YoY).
π Gilead beat consensus EPS and revenue estimates in each of the trailing four quarters.
π The Zacks Consensus Estimate for earnings has changed by -350.5% over the last 30 days.
π― Zacks Rank #3 (Hold) suggests the stock may perform in line with the broader market.
Bullish Signals
- Gilead beat consensus EPS estimates by +7.41% and revenue estimates by +0.95% in the last reported quarter.
- The company has topped both earnings and revenue consensus estimates for each of the trailing four quarters.
- Revenue growth is projected at +4.3% year-over-year for the current quarter and +6.4% for the next fiscal year.
- Gilead maintains a strong track record of beating analyst expectations over the last four quarters.
Risk Factors
- The company is expected to report a quarterly loss of $5.31 per share, representing a massive 364.2% year-over-year decline.
- Consensus earnings estimates for the current fiscal year have dropped significantly by 109.7% compared to the prior year.
- The Zacks Rank #3 (Hold) rating indicates the stock is expected to perform in line with the broader market rather than outperforming.
Full Analysis
Gilead Sciences (GILD) has recently attracted investor attention, appearing on Zacks.com's list of most searched stocks. Over the past month, GILD shares returned -4.4%, underperforming the S&P 500 composite which gained +5.4%. The broader medical-biomedical and genetics industry also declined by 2.9% during this period.
Zacks Investment Research prioritizes earnings estimate revisions to determine fair value, noting a strong correlation between these trends and short-term stock price movements. Currently, Gilead is expected to report a quarterly loss of $5.31 per share, representing a significant year-over-year decline of 364.2%. Over the last 30 days, the consensus earnings estimate has dropped by 350.5%.
Looking ahead, the consensus earnings estimate for the current fiscal year is -$0.79, down 109.7% from the prior year, while the next fiscal year's estimate stands at $9.53 with a slight upward revision of 0.6%. Revenue estimates show growth potential, with current quarter sales projected at $7.39 billion (+4.3% YoY) and full-year estimates of $30.37 billion (+3.1% YoY).
Gilead recently beat consensus estimates for both revenue and EPS in the last reported quarter, having topped expectations for the trailing four quarters consecutively. Based on these factors and the size of recent estimate changes, Zacks assigns Gilead a Rank #3 (Hold), suggesting the stock may perform in line with the broader market in the near term.